Actively Recruiting
Follow-up of Patients With Uveal Melanoma Adapted to the Risk of Relapse (SALOME)
Led by Institut Curie · Updated on 2025-09-03
700
Participants Needed
1
Research Sites
886 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Biomarkers search for early diagnosis of liver metastases in patients with uveal melanoma who benefit from a follow-up tailored to their personalized risk of relapse.
CONDITIONS
Official Title
Follow-up of Patients With Uveal Melanoma Adapted to the Risk of Relapse (SALOME)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient aged of 18 years or more.
- Patient with uveal melanoma with high metastatic relapse risk defined as T2b/c/d or T3, or chromosomal 3 or chromosomal 8 abnormality by CGH array.
- Completion of treatment of the primary tumor 2 months.
- Patient able to comply with the schedule of visits and blood samples of the study.
- Signed informed consent form or legal representative.
You will not qualify if you...
- Patient without French social insurance.
- Any social, medical or psychological condition making the research process impossible.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Institut Curie
Paris, France, 75005
Actively Recruiting
Research Team
S
Sophie Piperno-Neumann, MD
CONTACT
M
Marie-Emmanuelle Legrier, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
HEALTH_SERVICES_RESEARCH
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here